• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·5592.T
Share

Kusurinomadoguchi, Inc. Stocks

¥ 2421Last Updated 17.07.2026

Issuer Rating

5/7
Performance

Strong

Risk

Moderate

Recommendation

Hold

Market Cap

¥ 170.88M

¥ 2421
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Kusurinomadoguchi, Inc., established in 2004 and headquartered in Tokyo, Japan, develops and implements a diverse array of technology solutions specifically designed for pharmacies and the wider medical care sector throughout the country. Its comprehensive platform includes patient-facing services such as the EPARK drug counter, an online portal for locating and booking appointments at pharmacies, and the EPARK medicine notebook, which enables digital management of family prescriptions and reservation for medication dispensations. The company also offers a dedicated site facilitating telephone medical consultations for over-the-counter medicines, alongside a system allowing patients to select their preferred pharmacy for services, and provides online medication guidance as well as hospital-supported online consultations. For pharmacy operations and management, Kusurinomadoguchi delivers Health Tech Navi, an electronic medication history system, and the Care Daisy system, which integrates various recording tools and ICT devices. It further provides procurement solutions for pharmaceuticals, including a marketplace for dispensing pharmacies to efficiently buy and sell surplus or slow-moving inventory, extending to the management and acquisition of otherwise stagnant stock. The firm also features a centralized management system to streamline outpatient reception, appointment scheduling, and online medical treatments. Additionally, it offers Pharmacy Support, a robust customer relationship management (CRM) system tailored for engaging repeat patients, alongside specialized operational systems for dispensing pharmacies and a matching service connecting nursing care facilities with appropriate pharmacies.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.07.2026 15:45

Analysts recommended buying shares of a mid-cap drone manufacturer. What will drive its stock higher?

17.07.2026 15:15

Morning in New York: Pressure on the Tech Sector Persists

17.07.2026 14:55

Apple Shares Hit an All-Time High: Barron’s Compares the Company’s Strategy to Rockefeller’s Success

17.07.2026 14:21

The CEO of Microsoft, which has invested billions in Anthropic, criticized the company's new AI for censorship

17.07.2026 13:23

Small-Cap ETF Mid-Year Results: The Oil Rally Gave Way to Broad-Based Growth. Who Came Out on Top?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026